WO2004026324A1 - 抗アレルギー剤および抗炎症剤 - Google Patents
抗アレルギー剤および抗炎症剤 Download PDFInfo
- Publication number
- WO2004026324A1 WO2004026324A1 PCT/JP2003/011527 JP0311527W WO2004026324A1 WO 2004026324 A1 WO2004026324 A1 WO 2004026324A1 JP 0311527 W JP0311527 W JP 0311527W WO 2004026324 A1 WO2004026324 A1 WO 2004026324A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- snow
- agent
- genus
- hyaluronidase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the present invention relates to an anti-allergic agent, an anti-inflammatory agent, or a hyaluronidase activity inhibitor that can be used as food or drink for humans or animals, pharmaceuticals, and cosmetics. Background leakage
- the body has an immune function to maintain its homeostasis by eliminating extraneous substances from the outside.
- this immune function may act to damage the body, and a type of damage reaction caused by this excessive immune function is particularly called allergy. Allergy is caused by an overreaction of immunocompetent cells to causative substances derived from microorganisms, plants, animals, drugs, drugs, foods, etc., and activated salt hydration, mast cells, T lymphocytes, B lymphocytes Tissues in the body are damaged by physiologically active substances released from spheres and the like.
- the immediate allergic reaction can take a few minutes to several tens of minutes in a relatively short period of time, while the allergic reaction can be seen from a few hours later and then slowly over several days
- Progressive delayed alleles are divided into groups. Basophils in the blood, mast cells around blood vessels and in the joints have granules containing histamine, etc., and degranulation of these cells causes histamine and 0-hexosaminidase. It is known to release enzymes such as asthma and induce immediate allergic reactions such as asthma, hay fever and atopic eczema. In addition, substances released by these degranulations are well known as substances causing inflammation.
- Hyaluronic acid is a biological component that plays an extremely important role in the ontogeny and maintenance of Hosoya, as well as in the process of inflammatory response and wound healing.
- Hyaluronidase derived from snake venom pathogen is known as an enzyme that hydrolyzes hyaluronan, which is distributed abundantly in connective tissues of mammals.
- Hyaluronidase is activated during inflammation, works to destroy connective tissue and enhances cell and blood vessel permeability, and is known to inhibit allergic and inflammation by inhibiting the activity of hyaluronan nidase.
- Non-Patent Document 1 It has also been shown that hyaluronidase inhibitory activity is associated with inhibition of degranulation from mast cells (see Non-Patent No. 1 Dog 2). Therefore, measuring the hyaluronidase inhibitory activity is useful for assessing the anti-allergic and anti-inflammatory effects. Therefore, development of a hyaluronidase activity inhibitor has been required to provide useful anti-allergic agents and anti-inflammatory agents.
- hyaluronic acid is often contained in cosmetics such as emulsions and creams as a moisturizing agent, it is also desired to prevent hyaluronic acid in cosmetics by using a hyaluronidase inhibitor.
- the present inventors studied to provide a new antiallergic agent, an anti-inflammatory agent, and a hyaluronidase activity inhibitor, which are safe and can be easily S, and can be incorporated into cosmetics and foods and drinks. Advanced. Disclosure of the invention
- Inhibition of degranulation from basophils or mast cells as described above is expected to have an antiallergic effect, which can be performed by measuring the amount of histamine or) 3-hexosaminidase activity.
- Hyaluronidase inhibitory activity is expected to have anti-allergic, anti-inflammatory, or hyaluronic acid ⁇ ? Inhibitory effects.
- the present inventors have found that these problems can be solved by using a snow lotus extract, and have completed the present invention.
- a first aspect of the present invention relates to an antiallergic agent characterized by containing an extract of the genus Snow (Saussurea), and a method of inhibiting the extract of the genus Snow from basophil degranulation or obesity.
- the present invention relates to an antiallergic agent, which comprises an active ingredient for inhibiting cell degranulation or inhibiting hyaluronidase.
- the snow lotus is snow (Saussurea mvolucrata).
- the second aspect of the present invention relates to a hyaluronidase activity inhibitor comprising an extract of the genus Snow as a hyaluronidase inhibitory active ingredient, and a preferred embodiment is the above-mentioned Saussurea mvolucrata.
- the third aspect of the present invention relates to an anti-inflammatory agent characterized by containing an extract of the genus Snow Lotus as an active ingredient having a hyaluronidase inhibitory activity.
- a fourth aspect of the present invention relates to a food and drink, a cosmetic, and a bath containing at least one of the aforementioned antiallergic agent, hyaluronidase activity inhibitor, and antiinflammatory agent.
- Figure 1 shows the extract of] 3-hexosaminidase release inhibition and histamine release inhibition of extracts from snow stalks.
- the horizontal axis in FIG. 1 represents the scale factor of the snow lotus 70% ethanol extract, and the vertical axis represents the inhibition rate (%).
- the white bar on the left represents the inhibition of 0-hexosaminidase release
- the black bar on the right represents the inhibition of histamine release.
- Figure 2 shows the extracts from the extract from the snow flower that released / 3-hexosaminidase and hissamine.
- the horizontal axis of FIG. 2 represents the dilution ratio of snow 70% ethanol extract, and the vertical axis represents the inhibition rate (%).
- the white bar graph on the left side shows the inhibition rate of jS-hexosaminidase release, and the black bar graph on the right side shows the inhibition rate of hissumin release at each scale ratio.
- the production method of the genus Saussurea plant used in the present invention is not particularly limited.
- the snow genus i ⁇ ffi in the present invention may be not only native but also artificially cultivated.
- the extract of the genus Snow Lotus according to the present invention has an inhibitory activity on the release of hissamine and release of jS-hexosaminidase
- basophils have an inhibitory effect on degranulation from mast cells
- it has a hyaluronidase inhibitory activity and is therefore useful as an antiallergic or antiinflammatory agent. That is, histamine and i3-hexosaminidase are basophils
- histamine is one of the substances released from mast cells upon degranulation.
- histamine has the effect of causing a runny nose and causing skin and mucous membrane inflammation by expanding capillaries.
- hyaluronidase is a hydrolyzing enzyme that forms hyaluronic acid, which is distributed in the binding thread II. It is activated during inflammation, destroys the binding strand, and increases the permeability of cells and blood vessels. I have. Therefore, it is possible to exert anti-inflammatory and antiallergic effects by measuring hyalinidase activity.
- the extract of the present invention exhibits a hyaluronidase inhibitory activity and is therefore useful as a hyaluronidase inhibitor that suppresses the hyaluronic acid which has been converted from the hyaluronidase inhibitory activity.
- the activity of inhibiting halophilic cell glandular granule or mast cell degranulation is measured by the amount of histamine released by degranulation or the activity of] 3-hexosaminidase.
- histamine released using basophil cells such as KU812 shown in Example 1 is measured by capillary electrophoresis. After sensitizing cells with mouse anti-DNP-IgE antibody using basophils or mast cells as in Example 2, the released histamine was measured using DNP-BSA, an antigen. You may.
- the i3-hexosaminidase activity was released after sensitization of cells with a mouse anti-DNP-IgE antibody using a basophil cell such as KU812 shown in Example 2 , and using the antigen DNP-BSA / 3 —Measure hexosaminidase activity.
- mast cells may be used for the measurement of] 3-hexosaminidase activity.
- Hyaluronidase inhibitory activity is measured by the method according to Sawabe et al. (Hygiene Chemistry, 34 (4), 314-319, 1990).
- the snow genus used in the present invention may be used by selecting only one kind from among various kinds of production methods, or may be used by combining a plurality of kinds.
- the extract of the genus Snow Lotus is an extract of various parts of a plant body (whole plant, flower, stem, leaf, etc.) directly or with an extraction solvent.
- an organic solvent or vegetable oil can be used. Normal water and supercritical water can be used as the water.
- the organic solvent include alcohols (for example, lower alcohols such as ethanol and methanol, or polyhydric alcohols such as propylene alcohol), ketones such as acetate, and acetyl ether, dioxane, acetate nitrile, and ethyl acetate. Esters, xylene, benzene, black form and the like can be used.
- vegetable oils olive oil, coconut oil, safflower oil and the like can be used. These can be used alone or in any combination of two or more.
- solvent extracts can be used in combination with each other.
- the production method can be performed at room temperature and under normal pressure using an extraction solvent.After extraction, the extract is concentrated, concentrated, or oily, resulting in a solution, paste, gel, It may be in powder form. In some cases — 20. C to 100 ° C, preferably 1 to 80 ° (:, more preferably 20 to 6 Ot, 0.1 to 1 month, preferably 0.5 hour to 7 days, stirring or It is also possible to extract under supercritical conditions using carbon dioxide, etc. If necessary, it can be further purified by any operation using activated carbon column-ion resin.
- an extract obtained by extracting snow metal with hot water or ethanol can be used.
- the ethanol used for the extraction need not necessarily be pure ethanol. For example, it may contain 7j or an impurity, but must not contain a component that hinders extraction of the active substance.For example, 50% to 95% ethanol is preferable as aqueous ethanol, and 70% % Ethanol is more preferred.
- the amount of hot water or ethanol used for the extraction is preferably an amount that can sufficiently dissolve the active ingredient contained in the snow metal.
- the weight is preferably about 1 to 1000 times the weight of the snow genus plant used, 1 to 100 times is more preferable in that the extract li becomes higher. More preferably, it is 1 to 20 times.
- the collected snow lotus genus is washed to remove dirt and organisms attached to the surface, and then crushed by cutting, pole mill, ultrasonic treatment, homogenizer, etc., and then extracted. it can. Prior to crushing, air drying or freeze drying may be performed. It is preferable that the crushed snow lotus is repeatedly extracted several times with an extraction solvent such as hot water or ethanol.
- This extract can be used as it is as an antiallergic agent, a hyaluronidase activity inhibitor, or an antiinflammatory agent.
- the extract of the present invention can be used as a solution, a paste, a gel, or a powder by diluting or concentrating and drying as necessary.
- the extract of the present invention can be diluted with water or alcohol to be used as a water-soluble substance, or can be mixed with oils and fats to form a cream. Further, by powdering the extract, it can be made into a powdery antiallergic agent, hyaluronidase activity inhibitor, or antiinflammatory agent.
- the concentration and shape of the extract of the present invention are not particularly limited, and can be appropriately determined according to the use.
- the extract of the present invention may contain components other than the snow lotus extract. Since the extract of the present invention uses an extract of the genus Snow ⁇ ⁇ which is used for food as an active ingredient, it is highly safe for living organisms. For this reason, the extract of the present invention can be contained in a wide range of products such as pharmaceuticals, functional foods, foods and drinks, quasi-drugs, cosmetics, and bath preparations.
- the amount of the extract is not particularly limited, but the ili of the extract of the present invention in these products can be selected as long as the desired effect is obtained.
- the dosage can be, for example, 0.2 to 5 OmgZKg body weight per day, which can be administered in one to several doses, depending on the purpose of administration and administration route.
- Additives such as binders, excipients, lubricants, disintegrants, stabilizers, milking agents, and buffering agents that are generally used in pharmaceuticals Can contain the power.
- suitable binders include starch, trenolose, dextrin, and gum arabic.
- lubricant include stearic acid, talc, sucrose fatty acid ester, polyethylene glycol and the like.
- disintegrant include starch, carboxymethylcellulose, and starch.
- Suitable examples of the stabilizer include fats and oils, propylene glycol and the like.
- Preferred examples of the emulsifier include an anionic surfactant, a nonionic surfactant, and polyvinyl alcohol.
- Suitable examples of the buffer include buffers such as phosphate, carbonate, and citrate.
- the extract of the present invention can be contained in foods and drinks, cosmetics and bath preparations, and the content thereof is not particularly limited, but is usually 0.01% by weight or more, preferably 0.01% to 0.1% by weight. 60% by weight is good.
- the extract of the present invention is contained in cosmetics and used as an anti-allergic agent or anti-inflammatory agent, 0.01 to: 0% by weight of L, hyaluronic acid for inhibiting the degradation of hyaluronic acid contained in cosmetics
- it When used as an activity inhibitor, it can be adjusted to 1 to 100 ppm.
- bath preparations it may be prescribed so as to have a similar concentration according to the size of the bathtub.
- the extract of the present invention can be contained in a wet tissue, a mask, or the like at the same level of concentration.
- the food can be made into an anti-allergic functional food by including it in 0.1 to 50% by weight of the food.
- the type of the target food is not particularly limited as long as the antiallergic action of the extract is not inhibited.
- drinks such as juice, soft drinks, tea, etc., processed foods such as bread and rice cakes, sweets such as candy, instant foods such as cupramen, oils and fats such as butter and salad oil, dressings, mayonnaise
- sauces, seasonings such as soy sauce and mirin, sprinkles, and miso.
- it is also possible to grind the snow lotus as it is and to ingest it directly in addition to food.
- the dirt adhering to the surface is removed by thoroughly washing each 1 g of the dried flower 'stem' of the snow lotus flower (Saussurea involucrata). After cutting and crushing, put in 18% 70% ethanol as an extraction solvent, leave in a dark place not exposed to direct sunlight for 1 week, centrifuge at 4 ° C, 300 Orm for 5 minutes, The supernatant was filter sterilized. The extract was further diluted 100-fold, 100-fold, and 1000-fold with a cell culture medium.
- Human immature basophils (KU812) cells are seeded on RPMI-1640 medium supplemented with 10% FBS and 1% streptomycin, and cultured at 37 under 5% CO 2 .
- the supernatant was removed, and the histamine releasing buffer (30 mM Tris-HC1 pH 7.6, 120 mM NaC1, 5 mM KC1, 5 mM KC l, l mM CaC l 2, l mM MgC l 2, in 5% C_ ⁇ 2 after the 0.03% BSA) was added 20 Om 1, incubated for 30 minutes at 37 ° C carbon dioxide gas incubator in one . After incubation, centrifuge at 3000 rpm for 5 minutes at 4 ° C, and perform histamine-containing electrophoresis on the histamine-containing supernatant.
- the histamine releasing buffer (30 mM Tris-HC1 pH 7.6, 120 mM NaC1, 5 mM KC1, 5 mM KC l, l mM CaC l 2, l mM MgC l 2, in 5% C_ ⁇ 2 after the 0.03% BSA) was added 20 Om 1, incubated for 30 minutes at 37 ° C
- Histamine is a basic amine and is transferred to (+) in a buffer with a pH of 2.5.
- the histamine moves from the histamine standard solution and the test solution to the transfer time and the absorption spectrum (160 nm to 600 nm). After performing qualitative analysis, quantitative determination was performed based on the peak area of the standard solution.
- the standard solution of the histamine standard is 5 Omg of the histamine standard, made up to 5 Oml with distilled water.
- capillary electrophoresis a solution prepared by converting into pure water of 18.2 ⁇ . ⁇ to 0.05 ⁇ phosphoric acid is used as the electrophoresis running solution.
- Capillary Electro-Engaku uses a capillary electrophoresis device (manufactured by Yokogawa Hui Red Packard), column is phased silica, column is Capillary (Yokogawa Analytical System: 75 m inside diameter, effective wavelength 56 cm, full length) 64.5 cm),?
- Permanent buffer was 0.05 M phosphate buffer pH 7.5, voltage (30 kV; positive), sample 3 ⁇ 4 ⁇ amount (20,000 Pa.S (addition)), separation mode (capillary zone electrophoresis), detection wavelength ( Conditioning of the capillaries is performed by flushing with the sample 3 ⁇ 4 ⁇ for 5 minutes in running buffer.
- the results are shown in Figure 1.
- the snow extract of the present invention significantly inhibited the release of histamine from a salty salt demand, which is an indicator of antiallergic action.
- the cells were seeded in a 96-well plate at 100 lwell and incubated in a 37 ° C. carbon dioxide incubator under 5% CO 2 to sensitize the cells.
- the next day after washing cells twice with 200 H ⁇ of PBS, beta to one Kisosaminida Ichize release buffer one (116.9 mM NaC 1, 5.4 mM KC 1, 0.8 mM MgS0 4 ⁇ 7H 2 0, 5.6 mM glucose, 25 mM HEPES, 2.0 mM C a C 1 2, a 1.0 mg I ml BSA dissolved in 500 ml of water, adjusted to pH 7.7 with 10% N AHC_ ⁇ 3, create a filter one sterile ones) 60 ill production example 1 and snow extracted Mononanjishaku sample or control (PBS or 70% ethanol but was five times ⁇ in PBS) for 5 l Karoe, incubated 5% C0 2 under 10 minutes at 37 ° C carbon dioxide gas incubator in one I do.
- reaction stop solution 100 mM carbonate buffer; 100 ml of Na 2 C0 3 1.06 g I, 100 ml of NaHC ⁇ 3 0.84 g I
- the absorbance at 450 nm was measured using a microplate reader. Is measured.
- Inhibition rate (%) [l-(S-B) / (C-b)] X 100
- Solution C add a solution prepared by dissolving 1.83 mg of potassium salt of hyaluronic acid derived from turkey tosaka (Sigma machine) in 1 ml of 0.1 M acetate buffer (pH 40) ⁇ , and incubate at 37 ° C for 20 minutes. Then, add 0.1 ml of 0.4N NaOH aqueous solution and 0.1 ml of 0.8 M sodium borate (Na 2 B 4 ⁇ 7 ) solution and boil for 3 minutes.
- Table 1 shows the results.
- sample (2) is a mixture of equal amounts of flower / stem extract with 10 days of extraction according to the method of Production Example 1.
- the snow lotus extract of the present invention inhibited the hyaluronidase activity which is an indicator of the antiallergic action and m3 ⁇ 4 inflammatory action.
- sucrose fatty acid ester 5 parts by weight of sucrose fatty acid ester
- a woven IJ containing a snow extract was manufactured from the above-mentioned fibers by a conventional method.
- a soft capsule containing snow extract was woven with the above-mentioned fiber by a conventional method.
- (Prescription example 3) Manufacture of crackers containing snow extract Snow extract (S3 ⁇ 4t example 3) 1 part by weight
- a cracker containing snow extract was prepared by the conventional method with the above composition.
- a dressing containing a snow extract was produced in the above manner by a conventional method.
- (Formulation Example 5) Production of soft drink containing snow extract
- a soft drink containing the snow lotus extract was prepared by the usual method using the above composition. (Formulation Example 6) Production of chewing gum containing snow extract
- Chewing gum containing snow 3 ⁇ 4 ⁇ extract was prepared by the usual method with the above composition
- Emulsion containing snow extract was manufactured by the usual method as described above.
- a lotion containing a snow extract was manufactured with the above composition by a conventional method.
- (Formulation Example 9) Mii, a bath agent containing snow extract
- a bath agent containing a snow extract was manufactured by the above-mentioned pirates by a conventional method. Available on bell
- the snow extract described herein is useful as an anti-allergic agent, an anti-inflammatory agent or a hyaluronidase activity inhibitor.
- the extract of snow lotus of the present invention is highly safe and can be prepared by a simple method, so that it is highly applicable to pharmaceuticals, foods and drinks, cosmetics, bath agents, etc., and its application range is Expected to be very wide.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003262029A AU2003262029A1 (en) | 2002-09-20 | 2003-09-09 | Antiallergic agent and antiinflammatory agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-275497 | 2002-09-20 | ||
JP2002275497 | 2002-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004026324A1 true WO2004026324A1 (ja) | 2004-04-01 |
Family
ID=32025036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011527 WO2004026324A1 (ja) | 2002-09-20 | 2003-09-09 | 抗アレルギー剤および抗炎症剤 |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003262029A1 (ja) |
WO (1) | WO2004026324A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103125936A (zh) * | 2013-02-02 | 2013-06-05 | 安徽惠尔普生物科技发展有限责任公司 | 一种雪莲氨基酸营养口服液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5905089A (en) * | 1997-04-14 | 1999-05-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of sesquiterpene lactones for treatment of severe inflammatory disorders |
JP2001316240A (ja) * | 2000-05-11 | 2001-11-13 | Maruzen Pharmaceut Co Ltd | コラーゲン産生促進剤、エストロゲン様作用剤、皮膚化粧料および美容食品 |
JP2002201122A (ja) * | 2000-10-24 | 2002-07-16 | Maruzen Pharmaceut Co Ltd | 美白化粧料 |
-
2003
- 2003-09-09 WO PCT/JP2003/011527 patent/WO2004026324A1/ja not_active Application Discontinuation
- 2003-09-09 AU AU2003262029A patent/AU2003262029A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5905089A (en) * | 1997-04-14 | 1999-05-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of sesquiterpene lactones for treatment of severe inflammatory disorders |
JP2001316240A (ja) * | 2000-05-11 | 2001-11-13 | Maruzen Pharmaceut Co Ltd | コラーゲン産生促進剤、エストロゲン様作用剤、皮膚化粧料および美容食品 |
JP2002201122A (ja) * | 2000-10-24 | 2002-07-16 | Maruzen Pharmaceut Co Ltd | 美白化粧料 |
Non-Patent Citations (11)
Title |
---|
ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECT, vol. 12, pages 439 - 442 * |
CHUNG TS'AO YAO, vol. 12, no. 2, 1981, pages 30 * |
DATABASE CAPLUS [online] CHEN, X.Y. ET AL: "Studies on the anti-inflammatory and analgesic effects of xuelian (saussurea involucrata maxim) X injection.", XP002975818, accession no. stn Database accession no. 92:68659 * |
DATABASE CAPLUS [online] LI, G. ET AL: "Studies on pharmacological action of saussurea involucrata kar et kirex maxim", XP002975819, accession no. stn Database accession no. 92:66044 * |
DATABASE CAPLUS [online] MA, HONGJIE, FAN ET AL: "Effect of Saussurea involcucrata flavone on human peripheral blodd mononuclear cells.", XP002975817, accession no. stn Database accession no. 1998:581907 * |
HIROKO ISODA ET AL.: "Kyokugen kansochi biomass idenshi shigen no kaihatsu to yuko riyo (advanced application on functional natural resources arid land)", J. ARID LAND STUDIES, vol. 12, no. 4, 25 March 2003 (2003-03-25), pages 189 - 194, XP002975691 * |
ISODA H. ET AL.: "Inhibitory effect of a Chinese plant saussurea inrolucrata on hyaluronidase and on beta-hexosaminidase release from rat basophilic leukemia(RBL-2H3) cells", THE 13TH ANNUAL MEETING OF JAPANESE ASSOCIATION FOR ANIMAL CELL TECHNOLOGY (JAACT2000), 17 November 2000 (2000-11-17) - 21 November 2000 (2000-11-21), FUKUOKA JAPAN, XP002975811, Retrieved from the Internet <URL:http://agr.Kyushu-u.ac.jp/jaact/jaact2000/prcl.html> [retrieved on 20031007] * |
SEIICHI YAMAJI ET AL.: "Pharmacognostical studies on the Chinese crude drug 'Xuelianhua' and related etho-medicines(Part.I) On Chinese crude drug 'Xuelianhua' and tibetan crude drug 'Srol-going' derived from soroseris(compositae) plants", J. JPN. BOT., vol. 71, no. 5, 1996, pages 288 - 299, XP002975820 * |
SHUNJI AOKI ET AL.: "Mokko oyobi sono gan'yu seibun no kikan heikatsukin no taisuru sayo", JOURNAL OF MEDICAL AND PHARMACEUTIAL SOCIETY FOR WAKAN-YAKU, vol. 7, no. 3, 1990, pages 566 - 567, XP002975821 * |
XI'AN YIKE DAXUE XUEBAO, vol. 19, no. 2, 1998, pages 168 - 169 * |
YAO HSUEH HSUEH PAO, vol. 15, 1980, pages 368 - 370 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103125936A (zh) * | 2013-02-02 | 2013-06-05 | 安徽惠尔普生物科技发展有限责任公司 | 一种雪莲氨基酸营养口服液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003262029A1 (en) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009126863A (ja) | キノコから抽出したエルゴチオネインを高含有する組成物 | |
JP2006347985A (ja) | ニガナ及び/又はニガナの発酵処理物を含有する医薬品組成物 | |
KR102314654B1 (ko) | 항산화 활성이 증진된 발효 병풀 추출물을 유효성분으로 함유하는 피부주름 개선 또는 항염증용 조성물 | |
JP2007176814A (ja) | 炎症性サイトカイン産生抑制作用を有するゼアキサンチン誘導体、それからなる食品製剤、化粧品、抗炎症剤 | |
KR101793208B1 (ko) | 홍자단 추출물을 포함하는 항산화 또는 항염증 조성물 | |
KR102247810B1 (ko) | 락토바실러스 속 sdcm 1003 및 sdcm 1105의 혼합 균주, 그 배양액, 또는 이의 추출물을 유효성분으로 포함하는 조성물 | |
JP2011178770A (ja) | 皮膚の色素沈着を抑制する組成物およびその利用 | |
JP2009013106A (ja) | 炎症性サイトカイン産生抑制作用を有するキサントン誘導体、それらの製造方法、それからなる食品製剤、化粧品、抗炎症剤 | |
JP2007204444A (ja) | 炎症性サイトカイン産生抑制作用を有するピノセンブリンカルコン誘導体、それからなる食品製剤、化粧品、抗炎症剤 | |
KR20210066089A (ko) | 레몬 과피 추출물과 고삼 뿌리 추출물을 이용한 항염증용 조성물 | |
CN104666518A (zh) | 含有菊苣及枸桔的提取物的皮肤屏障强化用组合物 | |
JP4537024B2 (ja) | 炎症疾患予防・治療剤 | |
WO2004026324A1 (ja) | 抗アレルギー剤および抗炎症剤 | |
KR20230001597A (ko) | 햄프 줄기 발효추출물을 유효성분으로 함유하는 안티인플라메이징 조성물 | |
JPH11209295A (ja) | 抗アレルギー剤 | |
KR102007728B1 (ko) | 조릿대 추출물 또는 이의 분획을 유효성분으로 포함하는 알러지 질환 예방 또는 치료용 조성물 및 시약 조성물 | |
JP6300102B2 (ja) | 脂肪分解作用を有するジヒドロケンフェロール誘導体及びその製造方法 | |
KR102235186B1 (ko) | 발효 및 숙성한 코코넛 오일을 유효성분으로 함유하는 항염증용 조성물 및 이의 제조방법 | |
JP2010070531A (ja) | 天然抽出物より得られた脱顆粒抑制剤、β−ヘキソサミニダーゼ遊離抑制剤、抗アレルギー用または抗炎症用の食品、医薬、動物飼料用組成物および化粧品原料用組成物 | |
WO2005092357A1 (ja) | 抗アレルギー剤および抗炎症剤 | |
KR20160080513A (ko) | 줄풀 추출물을 이용한 항염증용 조성물 | |
JP5951077B2 (ja) | ヒアルロン酸合成促進剤 | |
JP2005089385A (ja) | リポキシゲナーゼ阻害剤 | |
EP2340844A1 (en) | Anti-avian influenza virus agent, and product containing anti-avian influenza virus agent | |
KR102428082B1 (ko) | 항염증 면역활성 및 항산화 활성을 가지며, 노인의 근력 또는 근육 강화를 위한 근세포 조성에 우수한 효과를 제공하는 프테로카리아 스테놉테라 추출물을 포함하는 화장료 조성물, 약학적 조성물, 및 식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |